Joint Venture Between Pharmaceutical Companies And Capital: Acceleration Of Research And Development Of New Global Crown Vaccine

The new crown pneumonia virus has no specific effect so far, and the vaccine will become the only hope. In the past six months, the new crown vaccine concept stock has been touted by the capital market.

Following the announcement of the clinical progress of the new crown vaccine following the announcement of the Wuhan biological products research institute and the biological products Research Institute of China, in June 23rd, the domestic vaccine Company Zhi Fei biological company announced that its new clinical trial of the new crown vaccine was approved. The news came out that the flying price of the flying creature was red, and it was on a straight line in two minutes, and the stock price was 108.01 yuan, which was a new high.

Internationally, in June 19th, GSK announced that the COVID-19 vaccine developed in collaboration with clover has also entered clinical trials, which has been funded by the CEPI. In June 9th, the Greek government announced an investment of US $1 million 600 thousand to support CEPI's development of COVID-19 vaccine.

Although vaccine development has been a long, risky and costly process, it can not stop the enthusiasm of all the people. By the end of April, more than 20 large and small enterprises announced the screening of virus strains and vaccine research and development. At the same time, the governments of various countries are funding, and the agencies and alliances cooperate with each other. Large and small pharmaceutical companies are joining the ranks, and different capital keeps coming in, making this vaccine racing more dazzling.

"Now let's look at some of the commercial logic of vaccine research and development companies. The first is that the new crown may become the same as influenza, and the vaccine may have some commercial prospects." Zhao Bing, chief analyst of Huajing securities pharmaceutical industry, told reporters in an interview with the economic news reporter twenty-first Century, "two is the participation of some companies. The demand for stock price is much more than commercial motivation. We also see that the price of vaccine related stocks has risen a lot. Three is the driving force of scientific research, and some vaccine giants are also involved in the strategic layout and brand investment. In the race to find vaccines.

Capital racing

In addition to announcing the latest trend, Chi Fei biology, in June 17th, benefited from the new crown virus inactivated vaccine developed by the China biological Wuhan Institute of biological products, and the share price of the 6 listed companies of the State Pharmaceutical Group rose collectively, and the A share vaccine also rose.

Since the outbreak of the new crown this year, Conchino, a vaccine star that churns capital markets, has returned several times at different time points.

For the capital market, the Zhao Bing analysis pointed out that the number of listed companies that have been vaccinated has gone up collectively. "In fact, the new crown vaccine is just a catalyst. The whole vaccine industry after the Changchun biological vaccine incident, until the introduction of the new vaccine management law, the more stringent control, means that the new entry to enter the industry, the threshold is getting higher and higher. It's a bit like the previous blood products industry, in other words, the companies that were originally there have become beneficiaries.

On the one hand, the vaccine can not rely entirely on imports. On the other hand, the domestic vaccine industry is still in the same level. It can not be killed by a single stick, but also based on domestic production. "In fact, in early 2019, the stock price of the whole industry began to reverse, and the epidemic situation catalyzed the rising speed of the capital market of the vaccine industry."

But capital will not give up chasing. For new innovative pharmaceutical companies, another important goal is to raise funds wherever possible. A good example is Moderna. When the company released the volunteer's early data in mid May, the market value soared 20% to nearly 30 billion dollars.

In April of this year, Moderna announced that it had received funding from US government agency BARDA up to US $483 million to speed up the development of mRNA vaccine against new coronavirus.

In May 5th, the new crown mRNA vaccine developed by Pfizer and the German Biotech Corp BioNTech announced the completion of the first batch of clinical trials in the United States. BioNTech sold the exclusive development and commercialization of the Chinese market to Fosun medicine with a license fee of $85 million.

This is another form of participation of "non vaccine enterprises".

Chen Qiyu, executive director and joint CEO of Fosun international, said in an interview with the twenty-first Century economic report that "before the Spring Festival, we will meet to discuss how to deal with the new crown epidemic situation. The consensus is that the mRNA vaccine may be a technical opportunity. Although we haven't had enough time to do it, we still have concerns and tracks on this technology platform. So immediately launched cooperation with the world's leading companies in this field. We haven't contacted traditional vaccines, all of them are vaccines of new technologies, all of which are nucleic acid technology companies. In the future, in fact, mRNA is just a cut in. It is a platform that will produce many products. We will continue to pay close attention to it. "

Fosun is responsible for the clinical trial, registration and sale of the vaccine in China, and will bear the corresponding costs and expenses. BioNTech will be responsible for the supply of products needed for clinical trials and commercialization in the region.

In April 22nd, BioNTech announced that it had been approved by German regulatory agency Paul-Ehrlich-Institut and could start its human clinical trials of its mRNA vaccine.

Global cooperation ecosystem

In terms of manpower and economy, new infectious diseases pose a growing threat to global health and safety. The cost of global pandemic is enormous. CEPI said that COVID-19 could make the global economy lose 4 trillion and 100 billion US dollars, accounting for 5% of global gross domestic product. Vaccines are one of the most powerful tools to fight epidemics.

In the face of the new crown virus, our advantage is "we have accumulated some experience and technology," said Gregory Poland, director of the vaccine research department of the Mayo Clinic and editor in chief of the Vaccine magazine. The related technology platform has been established, and the data available has been accumulated. However, as in other antiviral studies, these vaccines have not received sustained support from investors.

For example, a variety of vaccine candidates developed for SARS have never progressed to the 1 phase of clinical practice. However, he also believes that there are some methods for producing vaccines in the development of SARS vaccines: including adenovirus vaccine, vaccinia virus vaccine, virus like particle (VLP), whole virus vaccine, recombinant DNA vaccine, etc.

Large pharmaceutical companies with more experience are the first group to react quickly, and actively enter the process of finding vaccines. In addition to the traditional vaccine giant GSK, Senofi, Johnson, Pfizer, AstraZeneca and other multinational pharmaceutical companies have announced a number of cooperative vaccine development projects.

Effective therapies or vaccines will change the rules of the game. Many biopharmaceutical companies are pursuing this goal, which directly leads to the rapid development of cooperation between enterprises, academic institutions and non-profit organizations. For example, the vaccine cooperation between the two giants, Sanofi and GlaxoSmithKline, is an outstanding example of the integration of technology and profession by global competitors.

From the perspective of market size, "how big is the market for this acute infectious disease in the future? It is related to epidemic control." Zhao Bing believes that if the epidemic control is relatively good at home, it is unlikely that the whole population will be vaccinated, because large scale vaccination will definitely have allergies, though the ratio is very low, multiplying the population base of our country will still affect many people.

Even if a small company can develop a successful vaccine, most of the world's traditional vaccine production capacity is owned by a very small number of companies. If a preventive treatment for COVID-19 is found, and in order to deliver and distribute globally, WHO may turn to concentrate on the hands of several large global pharmaceutical companies.

?